28410411|t|Hepatitis C virus impairs natural killer cell activity via viral serine protease NS3
28410411|a|Hepatitis C virus (HCV) infection is characterized by a high frequency of chronic cases owing to the impairment of innate and adaptive immune responses. The modulation of natural killer (NK) cell functions by HCV leads to an impaired innate immune response. However, the underling mechanisms and roles of HCV proteins in this immune evasion are controversial, especially in the early phase of HCV infection. To investigate the role of HCV nonstructural proteins especially NS3 in the impairment of NK functions, NK cells were isolated from the PBMCs by negative selection. To assess the direct cytotoxicity and IFN-γ production capability of NK cells, co-cultured with uninfected, HCV-infected, HCV-NS3 DNA - transfected Huh-7.5, or HCV-NS replicon cells. To determine the effect of an NS3 serine protease inhibitor, HCV -infected Huh-7.5 cells were treated with BILN-2061. Then, NK cells were harvested and further co-cultured with K-562 target cells. NK cell functions were analyzed by flow cytometry and enzyme-linked immunosorbent assay. When co-cultured with HCV-infected Huh-7.5 cells, the natural cytotoxicity and IFN-γ production capability of NK cells were significantly reduced. NK cell functions were inhibited to similar levels upon co-culture with HCV-NS replicon cells, NS3 - transfected cells, and HCV-infected Huh-7.5 cells. These reductions were restored by BILN-2061 - treatment. Furthermore, BILN-2061 - treatment significantly increased degranulation against K-562 target cells and IFN-γ productivity in NK cells. Consistent with these findings, the expression levels of activating NK cell receptors, such as NKp46 and NKp30, were also increased. In HCV-infected cells, the serine protease NS3 may play a role in the abrogation of NK cell functions in the early phase of infection through downregulation of NKp46 and NKp30 receptors on NK cells. Together, these results suggest that NS3 represents a novel drug target for the treatment of HCV infections.
28410411	0	17	Hepatitis C virus	T005	C0220847
28410411	18	25	impairs	T169	C0221099
28410411	26	54	natural killer cell activity	T043	C1317556
28410411	55	58	via	T078	C1550513
28410411	59	84	viral serine protease NS3	T116,T126	C2717971
28410411	85	118	Hepatitis C virus (HCV) infection	T047	C4288963
28410411	141	145	high	T080	C0205250
28410411	146	155	frequency	T080	C1561548
28410411	159	166	chronic	T079	C0205191
28410411	167	172	cases	T169	C0868928
28410411	186	196	impairment	T169	C0221099
28410411	200	206	innate	T032	C0020969
28410411	211	236	adaptive immune responses	T043	C1155229
28410411	242	252	modulation	T080	C0205556
28410411	256	290	natural killer (NK) cell functions	T043	C1317556
28410411	294	297	HCV	T005	C0220847
28410411	310	318	impaired	T169	C0221099
28410411	319	341	innate immune response	T032	C0020969
28410411	366	376	mechanisms	T169	C0441712
28410411	381	386	roles	T170	C3871154
28410411	390	393	HCV	T005	C0220847
28410411	390	402	HCV proteins	T116,T123	C0042736
28410411	411	425	immune evasion	T040	C1654934
28410411	430	443	controversial	T054	C0680243
28410411	463	468	early	T079	C1279919
28410411	469	474	phase	T079	C0205390
28410411	478	491	HCV infection	T047	C4288963
28410411	496	507	investigate	T169	C1292732
28410411	512	516	role	T170	C3871154
28410411	520	523	HCV	T005	C0220847
28410411	520	546	HCV nonstructural proteins	T116,T123	C0069065
28410411	558	561	NS3	T116	C0249187
28410411	569	579	impairment	T169	C0221099
28410411	583	595	NK functions	T043	C1317556
28410411	597	605	NK cells	T025	C0022688
28410411	611	619	isolated	T169	C0205409
28410411	629	634	PBMCs	T025	C0599846
28410411	638	656	negative selection	T059	C2347338
28410411	661	667	assess	T052	C1516048
28410411	672	678	direct	T080	C1947931
28410411	679	691	cytotoxicity	T049	C0596402
28410411	696	712	IFN-γ production	T040	C1819433
28410411	713	723	capability	T080	C2698977
28410411	727	735	NK cells	T025	C0022688
28410411	737	748	co-cultured	T059	C0282547
28410411	766	778	HCV-infected	T025	C0007634
28410411	780	791	HCV-NS3 DNA	T114,T123	C0012854
28410411	794	805	transfected	T045	C0314641
28410411	806	813	Huh-7.5	T025	C0007634
28410411	818	824	HCV-NS	T116,T123	C0033684
28410411	825	833	replicon	T114,T123	C0035142
28410411	834	839	cells	T025	C0007634
28410411	858	864	effect	T080	C1280500
28410411	871	874	NS3	T116,T123	C0069065
28410411	875	900	serine protease inhibitor	T121,T123	C0036733
28410411	902	905	HCV	T005	C0220847
28410411	902	915	HCV -infected	T025	C0007634
28410411	916	929	Huh-7.5 cells	T025	C0007634
28410411	935	947	treated with	T061	C0332293
28410411	948	957	BILN-2061	T109	C1313841
28410411	965	973	NK cells	T025	C0022688
28410411	979	988	harvested	T059	C0022885
28410411	1001	1012	co-cultured	T059	C0282547
28410411	1018	1036	K-562 target cells	T025	C0600432
28410411	1038	1055	NK cell functions	T043	C1317556
28410411	1061	1069	analyzed	T062	C0936012
28410411	1073	1087	flow cytometry	T059	C0016263
28410411	1092	1125	enzyme-linked immunosorbent assay	T059	C0014441
28410411	1132	1143	co-cultured	T059	C0282547
28410411	1149	1161	HCV-infected	T047	C4288963
28410411	1162	1175	Huh-7.5 cells	T025	C0007634
28410411	1181	1188	natural	T169	C0205296
28410411	1189	1201	cytotoxicity	T049	C0596402
28410411	1206	1222	IFN-γ production	T040	C1819433
28410411	1223	1233	capability	T080	C2698977
28410411	1237	1245	NK cells	T025	C0022688
28410411	1274	1291	NK cell functions	T043	C1317556
28410411	1297	1306	inhibited	T080	C0311403
28410411	1318	1324	levels	T080	C0441889
28410411	1330	1340	co-culture	T059	C0282547
28410411	1346	1352	HCV-NS	T116,T123	C0033684
28410411	1353	1361	replicon	T114,T123	C0035142
28410411	1362	1367	cells	T025	C0007634
28410411	1369	1372	NS3	T116,T123	C0069065
28410411	1375	1386	transfected	T045	C0314641
28410411	1387	1392	cells	T025	C0007634
28410411	1398	1410	HCV-infected	T047	C4288963
28410411	1411	1424	Huh-7.5 cells	T025	C0007634
28410411	1432	1442	reductions	T080	C0392756
28410411	1460	1469	BILN-2061	T109	C1313841
28410411	1472	1481	treatment	T169	C0039798
28410411	1496	1505	BILN-2061	T109	C1313841
28410411	1508	1517	treatment	T169	C0039798
28410411	1532	1541	increased	T081	C0205217
28410411	1542	1555	degranulation	T043	C0007588
28410411	1564	1582	K-562 target cells	T025	C0600432
28410411	1587	1605	IFN-γ productivity	T040	C1819433
28410411	1609	1617	NK cells	T025	C0022688
28410411	1619	1634	Consistent with	T078	C0332290
28410411	1641	1649	findings	T033	C0243095
28410411	1655	1672	expression levels	T081	C3244092
28410411	1676	1686	activating	T052	C1879547
28410411	1687	1704	NK cell receptors	T116,T192	C2350463
28410411	1714	1719	NKp46	T116,T192	C2757033
28410411	1724	1729	NKp30	T116,T129,T192	C2757035
28410411	1741	1750	increased	T081	C0205217
28410411	1755	1767	HCV-infected	T047	C4288963
28410411	1768	1773	cells	T025	C0007634
28410411	1779	1798	serine protease NS3	T116,T126	C2717971
28410411	1810	1814	role	T170	C3871154
28410411	1836	1853	NK cell functions	T043	C1317556
28410411	1861	1866	early	T079	C1279919
28410411	1867	1872	phase	T079	C0205390
28410411	1876	1885	infection	T046	C3714514
28410411	1894	1908	downregulation	T044	C0013081
28410411	1912	1917	NKp46	T116,T192	C2757033
28410411	1922	1937	NKp30 receptors	T116,T129,T192	C2757035
28410411	1941	1949	NK cells	T025	C0022688
28410411	1988	1991	NS3	T116,T123	C0069065
28410411	1992	2002	represents	T052	C1882932
28410411	2005	2010	novel	T080	C0205314
28410411	2011	2022	drug target	T074	C0085104
28410411	2031	2040	treatment	T169	C0039798
28410411	2044	2058	HCV infections	T047	C4288963